March 12, 20240 citationsOpen Access

Supplementary Figure 1 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Key points are not available for this paper at this time.

Multi-epitope CD38-FITC binds CD38 in cells treated with SAR442257.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Keller et al. (Tue,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI에게 질문

Bookmark

View Full Paper